Allergic bronchopulmonary aspergillosis (ABPA) is an immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus. It clinically presents as chronic asthma, recurrent pulmonary infiltrates, and bronchiectasis. The prevalence of ABPA is believed to be around 1-2% in asthma patients and 2-15% in cystic fibrosis patients. ABPA results from an interplay between genetic susceptibility, environmental exposure to A. fumigatus antigens, and immunologic responses that lead to eosinophilic inflammation and tissue damage in the lungs. Diagnosis is based on criteria including asthma, pulmonary opacities, positive skin test or serum IgE levels to
this lecture( Allergic bronchopulmonary aspergillosis), has been presented by Dr.Anas azarmouh / azreig horpital. , that was in the event of Global asthma day 2018.
this lecture( Allergic bronchopulmonary aspergillosis), has been presented by Dr.Anas azarmouh / azreig horpital. , that was in the event of Global asthma day 2018.
Management of Chronic Pulmonary Aspergillosis and IgE for the LaypersonGraham Atherton
Professor Denning summarises how we manage CPA at the National Aspergillosis Centre, what we have learned, what we are still learning.
Graham Atherton describes IgE and how it affects Aspergillosis
Hypersensitivity pneumonitis: radiology and pathology aspectThorsang Chayovan
Hypersensitivity pneumonitis in the aspect of radiology and pathology: findings on imaging i.e. HRCT and pathologic characteristics and how to distinguish it from other differential diagnoses.
Comparing parts of UK & US Healthcare systems, IgG explainedGraham Atherton
NAC consultant Eavan Muldoon introduces herself as our new medic and talks a little about her background, part of which was spent at Tufts Medical Centre, Boston, USA. Then Graham Atherton talks about IgG, what they are and how they work.
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
Management of Chronic Pulmonary Aspergillosis and IgE for the LaypersonGraham Atherton
Professor Denning summarises how we manage CPA at the National Aspergillosis Centre, what we have learned, what we are still learning.
Graham Atherton describes IgE and how it affects Aspergillosis
Hypersensitivity pneumonitis: radiology and pathology aspectThorsang Chayovan
Hypersensitivity pneumonitis in the aspect of radiology and pathology: findings on imaging i.e. HRCT and pathologic characteristics and how to distinguish it from other differential diagnoses.
Comparing parts of UK & US Healthcare systems, IgG explainedGraham Atherton
NAC consultant Eavan Muldoon introduces herself as our new medic and talks a little about her background, part of which was spent at Tufts Medical Centre, Boston, USA. Then Graham Atherton talks about IgG, what they are and how they work.
World Allergy Week 2015: AIRWAY ALLERGIES The human and economic burdenJuan Carlos Ivancevich
Welcome! Join us during World Allergy Week 2015 and increase awareness of Airway Allergies - A Human and Economic Burden. There are many ways you can participate, and we hope you will explore this website, returning often, as it will continue to change.
The World Allergy Organization (WAO) is addressing the need for greater awareness and understanding of allergy topics as well as the exchange of ideas and collaboration in order to address treatment and quality-of-life issues related to the care of patients with allergic rhinitis and asthma.
It seems like you're providing information about the publication process of the International Journal of Advanced Publication Practices. This information outlines the fast publication schedule and peer-review process by the journal of the appears to prioritize a fast and efficient publication process while maintaining the quality and integrity of the research it publishes of the materials science journal.
It appears that you've provided a description of a journal that publishes research articles, reviews, and short communications in various fields related to Pharmaceutical Sciences and Biological Sciences of the ugc journal.
The submission process at IAJPB involves an initial rapid screening of submitted research articles by the journal's editors. This screening is typically done in consultation with the Editorial Board or experts in the relevant field to assess the articles' potential interest and importance for the journal is a scope of the original research paper.
International Journal of Pharmaceutical Science Invention (IJPSI)inventionjournals
is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf